ERBB2 and esophageal adenocarcinoma: Janjigian et al. (2025) presented updated Part 2 results from treatment-naïve patients with HER2+ gastric cancer, GEJA, or esophageal adenocarcinoma receiving T-DXd, pembrolizumab, and a fluoropyrimidine (5-FU or CAPE).